Although our work did not explore the involvement of cutaneous NLRP3 inflammasome and its downstream targets as the therapeutic mechanism of Nivea with STS supplementation, Karasawa et al. [36] recently reported NLRP3 inflammasome activation and subsequent pro-inflammatory cytokine release in an in vitro model of cryopyrin-associated periodic syndrome, an autoinflammatory condition characterized by cold-induced inflammation similar to frostbite. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.